EP4281486A4 - BICYCLIC PEPTIDES - Google Patents

BICYCLIC PEPTIDES

Info

Publication number
EP4281486A4
EP4281486A4 EP22741955.3A EP22741955A EP4281486A4 EP 4281486 A4 EP4281486 A4 EP 4281486A4 EP 22741955 A EP22741955 A EP 22741955A EP 4281486 A4 EP4281486 A4 EP 4281486A4
Authority
EP
European Patent Office
Prior art keywords
bicyclic peptides
new bicyclic
new
peptides
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22741955.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4281486A1 (en
Inventor
Sudha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900114A external-priority patent/AU2021900114A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of EP4281486A1 publication Critical patent/EP4281486A1/en
Publication of EP4281486A4 publication Critical patent/EP4281486A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP22741955.3A 2021-01-19 2022-01-19 BICYCLIC PEPTIDES Pending EP4281486A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021900114A AU2021900114A0 (en) 2021-01-19 Novel bicyclic peptipes
PCT/AU2022/050023 WO2022155704A1 (en) 2021-01-19 2022-01-19 Novel bicyclic peptides

Publications (2)

Publication Number Publication Date
EP4281486A1 EP4281486A1 (en) 2023-11-29
EP4281486A4 true EP4281486A4 (en) 2025-01-08

Family

ID=82548163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22741955.3A Pending EP4281486A4 (en) 2021-01-19 2022-01-19 BICYCLIC PEPTIDES

Country Status (9)

Country Link
US (1) US20240117005A1 (enExample)
EP (1) EP4281486A4 (enExample)
JP (1) JP2024504136A (enExample)
KR (1) KR20230146025A (enExample)
CN (1) CN117062842A (enExample)
AU (1) AU2022209878A1 (enExample)
CA (1) CA3208598A1 (enExample)
IL (1) IL304545A (enExample)
WO (1) WO2022155704A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023307414A1 (en) * 2022-07-13 2025-02-27 The Council Of The Queensland Institute Of Medical Research Novel inhibitors of histone methyltransferase nuclear localisation
CN121108243A (zh) * 2025-01-03 2025-12-12 中国药科大学 一种非核糖体多肽化合物及其合成基因簇bnp37和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2767730T3 (es) * 2015-04-30 2020-06-18 Univ Kyoto Método para predecir el efecto terapéutico del inhibidor PD-1/PD-L1 usando una anomalía en PD-L1(CD274) como índice
CA3001264A1 (en) * 2015-10-30 2017-05-04 Affibody Ab Pd-l1 binding polypeptide
EP3559018A1 (en) * 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
US20200339691A1 (en) * 2018-01-15 2020-10-29 Epiaxis Therapeutics Pty Ltd Proteinaceous molecules and uses therefor
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトpd−l1結合性ペプチド
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2024504136A (ja) 2024-01-30
IL304545A (en) 2023-09-01
US20240117005A1 (en) 2024-04-11
KR20230146025A (ko) 2023-10-18
WO2022155704A1 (en) 2022-07-28
AU2022209878A1 (en) 2023-09-07
CN117062842A (zh) 2023-11-14
EP4281486A1 (en) 2023-11-29
CA3208598A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
DK4464721T3 (da) Bicykliske heterotandem-peptidkomplekser
EP4225364A4 (en) Prefusion-stabilized hmpv f proteins
EP4028409A4 (en) NEW PEPTIDES
PL3810167T3 (pl) Bicykliczne ligandy peptydowe swoiste dla nektyny-4
IL305810A (en) Tumor neoantigenic peptides
DK3778621T3 (da) Peptidsyntesefremgangsmåde
IL281804A (en) Protein purification methods
IL305804A (en) Transmembrane neoantigenic peptides
EP3802852A4 (en) MANIPULATED CYCLIC PEPTIDES
EP4361141A4 (en) PROTEIN DEGRADING AGENT
IL314723A (en) Novel peptides
EP4349209A4 (en) PARASOL
EP3827116A4 (en) GENETICALLY ENCODED BICYCLIC PEPTIDE LIBRARIES
MA53498A (fr) Production de protéines recombinantes
DK3840767T3 (da) Peptider
EP4013440A4 (en) THERAPEUTIC PEPTIDES
DK3969206T3 (da) Kompositsliddel
EP4491731A4 (en) MODIFIED PROTEIN-GLUTAMINASE
EP4257597A4 (en) LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
EP4495244A4 (en) MODIFIED GLUTAMINASE PROTEIN
EP3864155A4 (en) NOVEL WHEAT CENH3 ALLELS
IL304545A (en) Novel bicyclic peptides
IL289460A (en) Modified bcl9 mimetic peptides
IL311773A (en) Peptide
IL311448A (en) Polypeptide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20241205

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20241129BHEP

Ipc: A61K 9/127 20060101ALI20241129BHEP

Ipc: A61K 38/00 20060101ALI20241129BHEP

Ipc: A61K 38/12 20060101ALI20241129BHEP

Ipc: A61K 38/16 20060101ALI20241129BHEP

Ipc: A61K 47/69 20170101ALI20241129BHEP

Ipc: A61P 35/00 20060101ALI20241129BHEP

Ipc: C07K 17/02 20060101AFI20241129BHEP